Belimumab, Azathioprine Did Not Lower Risk for Relapse in ANCA-Associated Vasculitis
Belimumab in combination with glucocorticoids and azathioprine did not lower the risk for relapse in patients with antineutrophil cytoplasm antibody-associated vasculitis.
Mycophenolate Mofetil Noninferior to Cyclophosphamide in ANCA-Associated Vasculitis
Mycophenolate mofetil was noninferior to cyclophosphamide for remission induction, but resulted in higher rates of relapse.
Survival Predictors Identified in Patients With Biopsy-Proven Giant Cell Arteritis
Researchers evaluated the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of patients with giant cell arteritis.
IgA Vasculitis Associated With Increased Risk for Hypertension, Chronic Kidney Disease
Patients with immunoglobulin A-associated vasculitis were at increased risk for hypertension and chronic kidney disease.
Vaccinations Not Linked to Childhood-Onset IgA Vasculitis
Vaccinations most frequently administered to children did not increase the risk for IgA vasculitis onset during the 3 months post-vaccination.
Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA
The FDA has approved updated labeling for Rituxan to include information on follow up treatment for patients with GPA and MPA who have achieved disease control with induction therapy.
Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment
Improved biomarkers are needed to monitor disease activity effectively in giant cell arteritis.
Improved Immune Response to Pneumococcal Vaccine in ANCA-Associated Vasculitis
Suppressing cytomegalovirus may improve the immune response to a T cell-dependent pneumococcal vaccination in patients experiencing ANCA-associated vasculitis.
Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition
Granulomatosis with polyangiitis was associated with an altered nasal microbial composition at both the bacterial and the fungal levels.
Examining Risk for Severe Infection in Rituximab-Treated AAV
Researchers observed severe infections in one-quarter of patients with AAV receiving rituximab.
Rheumatology Advisor Articles
- Vaccination Guidelines Released for Patients With Immune-Mediated Disorders
- Baricitinib Therapy in RA Not Associated With Adverse Cardiovascular Events
- Clinical, Radiographic Benefits of Tofacitinib Sustained for 2 Years in Rheumatoid Arthritis
- Axial Disease More Common in Psoriatic Arthritis With Acute Skin Manifestations
- Cardiovascular Safety in Gout: Interpreting Data From the CARES Trial
- Vaccination Guidelines Released for Patients With Immune-Mediated Disorders
- Does Cold Weather Affect Arthritis and Joint Pain?
- BMD Improved Significantly With Denosumab vs Bisphosphonates in Osteoporosis
- JAK Inhibitor Tapering in Rheumatoid Arthritis: Implications for Patients in Sustained Remission
- Yoga May Help With Rheumatoid Arthritis Symptoms, Severity
- Mycoplasma Pneumonia Increases Risk for Rheumatoid Arthritis
- Effectiveness of Biologic DMARDs in Rheumatoid Arthritis Compared
- Subchondral Pathology Independently Associated With Knee Osteoarthritis
- Yoga May Help With Rheumatoid Arthritis Symptoms, Severity
- Effects of Monetary Bonuses on Physician Care in Chronic Disease